Miyamoto et al found that ACE inhibitor and angiotensin II receptor blocker (ARB) antihypertensive treatment can improve FMD-assessed endothelial dysfunction better than other drug types.[23] In the present study, 3-month ACE inhibitor therapy has not resulted in significant changes in brachial artery FMD in hypertensive patients. The gene discussed is ACE; the disease is endothelial dysfunction.